Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy
S. Hong, C. Yu, P. Wang, Y. Shi, B. Cheng, M. CHEN, D. G. Chapla, N. Reigh, Y. Narimatsu, X. Chen, H. Clausen, K. W. Moremen, M. S. Macauley, J. C. Paulson, P. Wu
This study modifies NK cells with CD22 and selectin glycan ligands to enhance B-cell lymphoma targeting and trafficking, achieving effective tumor suppression in a xenograft model.
bioRxiv · Mar 23, 2020Bioengineering